Ocular Therapeutix targets Q4 2026 AXPAXLI NDA filing for wet AMD after FDA meeting
The company reported a May 2026 Type C meeting confirmed its SOL-1 trial with confirmatory evidence is sufficient for a wet AMD submission, and posted $598.6 million in cash as of June 30, 2026.
SEC filing